Antiepileptic mood stabilizers (AED-MS) are often used to treat bipolar disorder (BD). Similar to other mood disorder medications, AED-MS treatment response varies between patients. Identification of biomarkers associated with treatment response may ultimately help with the delivery of individualized treatment and lead to improved treatment efficacy. Here, we conducted a narrative review of the current knowledge of the pharmacogenomics of AED-MS (valproic acid, lamotrigine and carbamazepine) treatment response in BD, including genetic contributions to AED-MS pharmacokinetics. Genes involved in neurotransmitter systems and drug transport have been shown to be associated with AED-MS treatment response. As more studies are conducted, and experimental and analytical methods advance, knowledge of AED-MS pharmacogenomics is expected to grow and contribute to precision medicine in BD.

Keywords:

References

1. Leo RJ, Narendran R. Anticonvulsant use in the treatment of bipolar disorder: a primer for primary care physicians. Prim. Care Companion J. Clin. Psychiatry 1(3), 74–84 (1999).
MedlineGoogle Scholar
2. Ortiz A, Alda M. Treatment of bipolar disorder with comorbid migraine. J. Psychiatry Neurosci. 35(1), E1–E2 (2010).
MedlineGoogle Scholar
3. Frye MA, Salloum IM. Bipolar disorder and comorbid alcoholism: prevalence rate and treatment considerations. Bipolar Disord. 8(6), 677–685 (2006).
Medline CASGoogle Scholar
4. Al-Quliti KW. Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. Neurosciences 20(2), 107–114 (2015).
MedlineGoogle Scholar
5. Rybakowski JK. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge. CNS Drugs 27(3), 165–173 (2013).
Medline CASGoogle Scholar
6. Hou L, Heilbronner U, Degenhardt F et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet 387(10023), 1085–1093 (2016).
Medline CASGoogle Scholar
7. Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin. Neurol. Neurosurg. 112(4), 320–323 (2010).
MedlineGoogle Scholar
8. Ho PC, Abbott FS, Zanger UM, Chang TK. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J. 3(6), 335–342 (2003).
Medline CASGoogle Scholar
9. Krishnaswamy S, Hao Q, Al-Rohaimi A et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J. Pharmacol. Exp. Ther. 313(3), 1340–1346 (2005).
Medline CASGoogle Scholar
10. Wang P, Lin XQ, Cai WK et al. Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis. Eur. J. Clin. Pharmacol. 74(4), 433–442 (2018).
Medline CASGoogle Scholar
11. Stewart JD, Horvath R, Baruffini E et al. Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52(5), 1791–1796 (2010).
Medline CASGoogle Scholar
12. Ho AM, Coombes BJ, Nguyen TTL et al. Mood-stabilizing antiepileptic treatment response in bipolar disorder: a genome-wide association study. Clin. Pharmacol. Ther. 108(6), 1233–1242 (2020).
Medline CASGoogle Scholar
13. Lee HY, Kim YK. Catechol-O-methyltransferase Val158Met polymorphism affects therapeutic response to mood stabilizer in symptomatic manic patients. Psychiatry Res. 175(1–2), 63–66 (2010).
Medline CASGoogle Scholar
14. Kim B, Kim CY, Lee MJ, Joo YH. Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. Psychiatry Res. 168(3), 209–212 (2009).
Medline CASGoogle Scholar
15. Lovric M, Bozina N, Hajnsek S et al. Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. Ther. Drug Monit. 34(5), 518–525 (2012).
Medline CASGoogle Scholar
16. Zhou Y, Wang X, Li H et al. Polymorphisms of ABCG2, ABCB1 and HNF4alpha are associated with Lamotrigine trough concentrations in epilepsy patients. Drug Metab. Pharmacokinet. 30(4), 282–287 (2015).
Medline CASGoogle Scholar
17. Shen CH, Zhang YX, Lu RY et al. Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. Epilepsy Res. 127, 186–190 (2016).
Medline CASGoogle Scholar
18. Ortega-Vazquez A, Fricke-Galindo I, Dorado P et al. Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy. Pharmacogenomics J. 20, 845–856 (2020).
Medline CASGoogle Scholar
19. Perlis RH, Adams DH, Fijal B et al. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J. Clin. Psychiatry 71(5), 599–605 (2010).
Medline CASGoogle Scholar
20. Djordjevic N, Milovanovic DD, Radovanovic M et al. CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy. Eur. J. Clin. Pharmacol. 72(4), 439–445 (2016).
Medline CASGoogle Scholar
21. Chbili C, Fathallah N, Laouani A et al. Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients. J. Neurogenet. 30(1), 16–21 (2016).
Medline CASGoogle Scholar
22. Park PW, Seo YH, Ahn JY, Kim KA, Park JY. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J. Clin. Pharm. Ther. 34(5), 569–574 (2009).
Medline CASGoogle Scholar
23. Ganesapandian M, Ramasamy K, Adithan S, Narayan SK. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population. Indian J. Pharmacol. 51(6), 384–388 (2019).
Medline CASGoogle Scholar
24. Hung CC, Chang WL, Ho JL et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics 13(2), 159–169 (2012).
CASGoogle Scholar
25. Daci A, Beretta G, Vllasaliu D et al. Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of kosovar albanian epileptic patients. PLoS ONE 10(11), e0142408 (2015).
MedlineGoogle Scholar
26. Yun W, Zhang F, Hu C et al. Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Res. 107(3), 231–237 (2013).
Medline CASGoogle Scholar
27. Ma CL, Jiao Z, Wu XY, Hong Z, Wu ZY, Zhong MK. Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy. Pharmacogenomics 16(13), 1499–1512 (2015).
CASGoogle Scholar
28. Lu Q, Huang YT, Shu Y et al. Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients. Medicine (Baltimore) 97(30), e11662 (2018).
Medline CASGoogle Scholar
29. Fricke-Galindo I, Martinez-Juarez IE, Monroy-Jaramillo N et al. HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients. Pharmacogenomics 15(15), 1881–1891 (2014).
CASGoogle Scholar
30. Nicoletti P, Barrett S, McEvoy L et al. Shared genetic risk factors across carbamazepine-induced hypersensitivity reactions. Clin. Pharmacol. Ther. 106(5), 1028–1036 (2019).
Medline CASGoogle Scholar
31. Ramirez E, Bellon T, Tong HY et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol. Res. 115, 168–178 (2017).
Medline CASGoogle Scholar
32. Kim SH, Lee KW, Song WJ et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 97(1–2), 190–197 (2011).
Medline CASGoogle Scholar
33. Mushiroda T, Takahashi Y, Onuma T et al. Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population. JAMA Neurol. 75(7), 842–849 (2018).
MedlineGoogle Scholar
34. Man CB, Kwan P, Baum L et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48(5), 1015–1018 (2007).
Medline CASGoogle Scholar
35. Hung SI, Chung WH, Jee SH et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16(4), 297–306 (2006).
Medline CASGoogle Scholar
36. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7(6), 813–818 (2006).
CASGoogle Scholar
37. Lonjou C, Thomas L, Borot N et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 6(4), 265–268 (2006).
Medline CASGoogle Scholar
38. Chung WH, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982), 486 (2004).
Medline CASGoogle Scholar
39. Ghodke-Puranik Y, Thorn CF, Lamba JK et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics 23(4), 236–241 (2013).
Medline CASGoogle Scholar
40. Turgut G, Kurt E, Sengul C et al. Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. Mol. Biol. Rep. 36(3), 495–499 (2009).
Medline CASGoogle Scholar
41. Zhao M, Zhang T, Li G, Qiu F, Sun Y, Zhao L. Associations of CYP2C9 and CYP2A6 polymorphisms with the concentrations of valproate and its hepatotoxin metabolites and valproate-induced hepatotoxicity. Basic Clin. Pharmacol. Toxicol. 121(2), 138–143 (2017).
Medline CASGoogle Scholar
42. Dinopoulos A, Karapanou O, Alexopoulou E, Tzetis M, Attilakos A, Fretzayas A. VPA-induced recurrent pancreatitis in a cystic fibrosis carrier. Eur. J. Paediatr. Neurol. 15(5), 453–455 (2011).
MedlineGoogle Scholar
43. López-Muñoz F, Shen WW, D'Ocon P, Romero A, Álamo C. A history of the pharmacological treatment of bipolar disorder. Int. J. Mol. Sci. 19(7), 2143 (2018).
Google Scholar
44. Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev. 9(2), 199–216 (2003).
Medline CASGoogle Scholar
45. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 10(7), 685–692 (2004).
Medline CASGoogle Scholar
46. Schloesser RJ, Huang J, Klein PS, Manji HK. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33(1), 110–133 (2008).
Medline CASGoogle Scholar
47. Jun C, Choi Y, Lim SM et al. Disturbance of the glutamatergic system in mood disorders. Exp. Neurobiol. 23(1), 28–35 (2014).
MedlineGoogle Scholar
48. Petty F. GABA and mood disorders: a brief review and hypothesis. J. Affect. Disord. 34(4), 275–281 (1995).
Medline CASGoogle Scholar
49. Machado-Vieira R, Ibrahim L, Zarate CA Jr. Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. CNS Neurosci. Ther. 17(6), 699–704 (2011).
Medline CASGoogle Scholar
50. Arent CO, Valvassori SS, Fries GR et al. Neuroanatomical profile of antimaniac effects of histone deacetylases inhibitors. Mol. Neurobiol. 43(3), 207–214 (2011).
Medline CASGoogle Scholar
51. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J. Neurosci. 28(10), 2576–2588 (2008).
Medline CASGoogle Scholar
52. Grof P, Duffy A, Cavazzoni P et al. Is response to prophylactic lithium a familial trait? J. Clin. Psychiatry 63(10), 942–947 (2002).
Medline CASGoogle Scholar
53. Kakiuchi C, Iwamoto K, Ishiwata M et al. Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nat. Genet. 35(2), 171–175 (2003).
Medline CASGoogle Scholar
54. Masui T, Hashimoto R, Kusumi I et al. A possible association between the −116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int. J. Neuropsychopharmacol. 9(1), 83–88 (2006).
Medline CASGoogle Scholar
55. Dickens D, Owen A, Alfirevic A et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem. Pharmacol. 83(6), 805–814 (2012).
Medline CASGoogle Scholar
56. Luna-Tortos C, Fedrowitz M, Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55(8), 1364–1375 (2008).
Medline CASGoogle Scholar
57. Suzuki T, Mihara K, Nagai G et al. Relationship between UGT1A4 and UGT2B7 polymorphisms and the steady-state plasma concentrations of lamotrigine in patients with treatment-resistant depressive disorder receiving lamotrigine as augmentation therapy. Ther. Drug Monit. 41(1), 86–90 (2019).
Medline CASGoogle Scholar
58. Wang X-Q, Shi X-B, Au R, Chen F-S, Wang F, Lang S-Y. Influence of chemical structure on skin reactions induced by antiepileptic drugs – the role of the aromatic ring. Epilepsy Res. 94(3), 213–217 (2011).
Medline CASGoogle Scholar
59. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome. Drug Saf. 21(6), 489–501 (1999).
Medline CASGoogle Scholar
60. Deng Y, Li S, Zhang L, Jin H, Zou X. Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: a meta-analysis. Seizure 60, 163–171 (2018).
MedlineGoogle Scholar
61. Li W, Wang J, Lin H, Shen G. HLA-A *24:02 associated with lamotrigine-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. Medicine (Baltimore) 99(52), e23929 (2020).
Medline CASGoogle Scholar
62. Li X, Yu K, Mei S et al. HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies. Drug Res. (Stuttg.) 65(2), 107–111 (2015).
Medline CASGoogle Scholar
63. Ito A, Shimada H, Ishikawa K et al. Association between HLA-DRB1*0405, -DQB1*0401 and -DQA1*0303 alleles and lamotrigine-induced cutaneous adverse drug reactions. A pilot case-control study from Japan. J. Affect. Disord. 179, 47–50 (2015).
Medline CASGoogle Scholar
64. Kim BK, Jung JW, Kim TB et al. HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population. Ann. Allergy Asthma Immunol. 118(5), 629–630 (2017).
Medline CASGoogle Scholar
65. Park HJ, Kim YJ, Kim DH et al. HLA allele frequencies in 5802 Koreans: varied allele types associated with SJS/TEN according to culprit drugs. Yonsei Med. J. 57(1), 118–126 (2016).
Medline CASGoogle Scholar
66. Buyukozturk S, Kekik C, Gokyigit AZ et al. Cutaneous drug reactions to antiepileptic drugs and relation with HLA alleles in the Turkish population. Eur. Ann. Allergy Clin. Immunol. 50(1), 36–41 (2018).
Medline CASGoogle Scholar
67. Prabhavalkar KS, Poovanpallil NB, Bhatt LK. Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer. Front. Pharmacol. 6, 242 (2015).
MedlineGoogle Scholar
68. Stefani A, Hainsworth AH, Spadoni F, Bernardi G. On the inhibition of voltage activated calcium currents in rat cortical neurones by the neuroprotective agent 619C89. Br. J. Pharmacol. 125(5), 1058–1064 (1998).
Medline CASGoogle Scholar
69. Kuo CC, Lu L. Characterization of lamotrigine inhibition of Na⁺ channels in rat hippocampal neurones. Br. J. Pharmacol. 121(6), 1231–1238 (1997).
Medline CASGoogle Scholar
70. Waldmeier PC, Martin P, Stocklin K, Portet C, Schmutz M. Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Naunyn Schmiedebergs Arch. Pharmacol. 354(2), 164–172 (1996).
Medline CASGoogle Scholar
71. Sitges M, Guarneros A, Nekrassov V. Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca²⁺ channel-mediated release of [3H]glutamate: comparison with the Na⁺ channel-mediated release. Neuropharmacology 53(7), 854–862 (2007).
Medline CASGoogle Scholar
72. Lee CY, Fu WM, Chen CC, Su MJ, Liou HH. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia 49(5), 888–897 (2008).
Medline CASGoogle Scholar
73. Kuzniecky R, Ho S, Pan J et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 58(3), 368–372 (2002).
Medline CASGoogle Scholar
74. Wang JF, Sun X, Chen B, Young LT. Lamotrigine increases gene expression of GABA-A receptor beta3 subunit in primary cultured rat hippocampus cells. Neuropsychopharmacology 26(4), 415–421 (2002).
Medline CASGoogle Scholar
75. Southam E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur. J. Pharmacol. 358(1), 19–24 (1998).
Medline CASGoogle Scholar
76. Ahmad S, Fowler LJ, Whitton PS. Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res. 63(2–3), 141–149 (2005).
Medline CASGoogle Scholar
77. Pohjalainen T, Rinne JO, Någren K et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 3(3), 256–260 (1998).
Medline CASGoogle Scholar
78. Thompson J, Thomas N, Singleton A et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7(6), 479–484 (1997).
Medline CASGoogle Scholar
79. Kamei C. Involvement of central histamine in amygdaloid kindled seizures in rats. Behav. Brain Res. 124(2), 243–250 (2001).
Medline CASGoogle Scholar
80. Ago J, Ishikawa T, Matsumoto N, Ashequr Rahman M, Kamei C. Mechanism of imipramine-induced seizures in amygdala-kindled rats. Epilepsy Res. 72(1), 1–9 (2006).
Medline CASGoogle Scholar
81. Gragnoli C. Hypothesis of the neuroendocrine cortisol pathway gene role in the comorbidity of depression, Type 2 diabetes, and metabolic syndrome. Appl. Clin. Genet. 7, 43–53 (2014).
MedlineGoogle Scholar
82. Szczepankiewicz A, Rybakowski JK, Suwalska A, Hauser J. Glucocorticoid receptor polymorphism is associated with lithium response in bipolar patients. Neuro. Endocrinol. Lett. 32(4), 545–551 (2011).
Medline CASGoogle Scholar
83. Uher R, Huezo-Diaz P, Perroud N et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 9(4), 225–233 (2009).
Medline CASGoogle Scholar
84. Tomson T, Tybring G, Bertilsson L. Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. Clin. Pharmacol. Ther. 33(1), 58–65 (1983).
Medline CASGoogle Scholar
85. Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR. A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. J. Res. Med. Sci. 18(Suppl. 1), S81–S85 (2013).
MedlineGoogle Scholar
86. Ihtisham K, Ramanujam B, Srivastava S et al. Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population. Seizure 66, 99–103 (2019).
MedlineGoogle Scholar
87. Sukasem C, Chaichan C, Nakkrut T et al. Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients. J. Immunol. Res. 2018, 2780272 (2018).
MedlineGoogle Scholar
88. Shi YW, Min FL, Zhou D et al. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology 88(23), 2183–2191 (2017).
Medline CASGoogle Scholar
89. Sun D, Yu CH, Liu ZS et al. Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China. J. Huazhong Univ. Sci. Technolog. Med. Sci. 34(1), 146–150 (2014).
Medline CASGoogle Scholar
90. Weisler RH. Carbamazepine extended-release capsules in bipolar disorder. Neuropsychiatr. Dis. Treat. 2(1), 3–11 (2006).
Medline CASGoogle Scholar
91. Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 25(2), 228–234 (1984).
Medline CASGoogle Scholar
92. McLean MJ, Macdonald RL. Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 238(2), 727–738 (1986).
Medline CASGoogle Scholar
93. Gasior M, Kleinrok Z, Czuczwar SJ. Influence of BAY k-8644, a calcium channel agonist, on the anticonvulsant activity of conventional anti-epileptics against electroconvulsions in mice. Neuropharmacology 34(4), 433–438 (1995).
Medline CASGoogle Scholar
94. Kito M, Maehara M, Watanabe K. Antiepileptic drugs – calcium current interaction in cultured human neuroblastoma cells. Seizure 3(2), 141–149 (1994).
Medline CASGoogle Scholar
95. Yoshida S, Okada M, Zhu G, Kaneko S. Carbamazepine prevents breakdown of neurotransmitter release induced by hyperactivation of ryanodine receptor. Neuropharmacology 52(7), 1538–1546 (2007).
Medline CASGoogle Scholar
96. Granger P, Biton B, Faure C et al. Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol. Pharmacol. 47(6), 1189–1196 (1995).
Medline CASGoogle Scholar
97. Motohashi N. GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate. Prog. Neuropsychopharmacol. Biol. Psychiatry 16(4), 571–579 (1992).
Medline CASGoogle Scholar
98. Lampe H, Bigalke H. Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport 1(1), 26–28 (1990).
Medline CASGoogle Scholar
99. Lancaster JM, Davies JA. Carbamazepine inhibits NMDA-induced depolarizations in cortical wedges prepared from DBA/2 mice. Experientia 48(8), 751–753 (1992).
Medline CASGoogle Scholar
100. Okada M, Kawata Y, Mizuno K, Wada K, Kondo T, Kaneko S. Interaction between Ca²⁺, K⁺, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br. J. Pharmacol. 124(6), 1277–1285 (1998).
Medline CASGoogle Scholar
101. Yamamura S, Hamaguchi T, Ohoyama K et al. Topiramate and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin. Epilepsy Res. 84(2–3), 172–186 (2009).
Medline CASGoogle Scholar
102. Kawata Y, Okada M, Murakami T, Kamata A, Zhu G, Kaneko S. Pharmacological discrimination between effects of carbamazepine on hippocampal basal, Ca(²⁺)- and K(⁺)-evoked serotonin release. Br. J. Pharmacol. 133(4), 557–567 (2001).
Medline CASGoogle Scholar
103. Dailey JW, Reith ME, Steidley KR, Milbrandt JC, Jobe PC. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia 39(10), 1054–1063 (1998).
Medline CASGoogle Scholar
104. Dailey JW, Reith ME, Yan QS, Li MY, Jobe PC. Anticonvulsant doses of carbamazepine increase hippocampal extracellular serotonin in genetically epilepsy-prone rats: dose response relationships. Neurosci. Lett. 227(1), 13–16 (1997).
Medline CASGoogle Scholar
105. Barros HM, Braz S, Leite JR. Effect of carbamazepine on dopamine release and reuptake in rat striatal slices. Epilepsia 27(5), 534–537 (1986).
Medline CASGoogle Scholar
106. Ichikawa J, Meltzer HY. Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation. Eur. J. Pharmacol. 380(1), R1–3 (1999).
Medline CASGoogle Scholar
107. Baf MH, Subhash MN, Lakshmana KM, Rao BS. Alterations in monoamine levels in discrete regions of rat brain after chronic administration of carbamazepine. Neurochem. Res. 19(9), 1139–1143 (1994).
Medline CASGoogle Scholar
108. Biber K, Fiebich BL, Gebicke-Harter P, van Calker D. Carbamazepine-induced upregulation of adenosine A1-receptors in astrocyte cultures affects coupling to the phosphoinositol signaling pathway. Neuropsychopharmacology 20(3), 271–278 (1999).
Medline CASGoogle Scholar
109. Zangrossi H Jr, Leite JR, Graeff FG. Anxiolytic effect of carbamazepine in the elevated plus-maze: possible role of adenosine. Psychopharmacology (Berl.) 106(1), 85–89 (1992).
Medline CASGoogle Scholar
110. Fujiwara Y, Sato M, Otsuki S. Interaction of carbamazepine and other drugs with adenosine (A1 and A2) receptors. Psychopharmacology (Berl.) 90(3), 332–335 (1986).
Medline CASGoogle Scholar
111. Krarup S, Mertz C, Jakobsen E, Lindholm SEH, Pinborg LH, Bak LK. Distinct effects on cAMP signaling of carbamazepine and its structural derivatives do not correlate with their clinical efficacy in epilepsy. Eur. J. Pharmacol. 886, 173413 (2020).
Medline CASGoogle Scholar
112. Chen G, Pan B, Hawver DB, Wright CB, Potter WZ, Manji HK. Attenuation of cyclic AMP production by carbamazepine. J. Neurochem. 67(5), 2079–2086 (1996).
Medline CASGoogle Scholar
113. Teo R, King J, Dalton E, Ryves J, Williams RS, Harwood AJ. PtdIns(3,4,5)P(3) and inositol depletion as a cellular target of mood stabilizers. Biochem. Soc. Trans. 37(Pt 5), 1110–1114 (2009).
Medline CASGoogle Scholar
114. Manchia M, Adli M, Akula N et al. Assessment of response to lithium maintenance treatment in bipolar disorder: a Consortium on Lithium Genetics (ConLiGen) report. PLoS ONE 8(6), e65636 (2013).
Medline CASGoogle Scholar
115. Kuo M-W, Wang C-H, Wu H-C, Chang S-J, Chuang Y-J. Soluble THSD7A is an N-glycoprotein that promotes endothelial cell migration and tube formation in angiogenesis. PLoS ONE 6(12), e29000 (2011).
Medline CASGoogle Scholar
116. Stahl E, Breen G, Forstner A et al. Genomewide association study identifies 30 loci associated with bipolar disorder. Nat. Genet. 51, 793–803 (2019).
Medline CASGoogle Scholar
117. Martins-de-Souza D, Solari FA, Guest PC, Zahedi RP, Steiner J. Biological pathways modulated by antipsychotics in the blood plasma of schizophrenia patients and their association to a clinical response. NPJ Schizophr. 1, 15050 (2015).
MedlineGoogle Scholar
118. Lee Y, Zhang Y, Kim S, Han K. Excitatory and inhibitory synaptic dysfunction in mania: an emerging hypothesis from animal model studies. Exp. Mol. Med. 50(4), 12 (2018).
Google Scholar
119. Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu. Rev. Pharmacol. Toxicol. 54, 95–117 (2014).
Medline CASGoogle Scholar
120. Luna-Tortos C, Fedrowitz M, Loscher W. Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 58(7), 1019–1032 (2010).
Medline CASGoogle Scholar
121. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther. 320(1), 331–343 (2007).
Medline CASGoogle Scholar
122. Lichou F, Trynka G. Functional studies of GWAS variants are gaining momentum. Nat. Commun. 11(1), 6283 (2020).
Medline CASGoogle Scholar
123. Zhou Y, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke VM. An optimized prediction framework to assess the functional impact of pharmacogenetic variants. Pharmacogenomics J. 19(2), 115–126 (2019).
Medline CASGoogle Scholar
124. Powell SK, Gregory J, Akbarian S, Brennand KJ. Application of CRISPR/Cas9 to the study of brain development and neuropsychiatric disease. Mol. Cell. Neurosci. 82, 157–166 (2017).
Medline CASGoogle Scholar
125. Low LA, Mummery C, Berridge BR, Austin CP, Tagle DA. Organs-on-chips: into the next decade. Nat. Rev. Drug Discov. 20, 345–361 (2020).
MedlineGoogle Scholar
126. Lin E, Lin CH, Lane HY. Precision psychiatry applications with pharmacogenomics: artificial intelligence and machine learning approaches. Int. J. Mol. Sci. 21(3), 969 (2020).
Google Scholar

Vol. 22, No. 14

Supplemental Materials

Metrics

Downloaded 294 times

History

Received 24 March 2021

Accepted 12 August 2021

Published online 6 September 2021

Published in print September 2021

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/pgs-2021-0041

Author contributions

AM-C Ho and JM Biernacka formed the concept of the work. AM-C Ho prepared the manuscript. RM Weinshilboum, MA Frye and JM Biernacka provided critical revision and important intellectual content. All authors approved the final version to be published and agreed to be accountable for all aspects the work.

Financial & competing interests disclosure

This research is supported by a gift from Kent and Liz Dauten and the Mayo Clinic Center for Individualized Medicine. RM Weinshilboum is a founder and shareholder in OneOme LLC, a pharmacogenomics decision support company. MA Frye has received grant support from Assurex Health, Myriad, Pfizer, Marriott Foundation and Mayo Foundation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Genetics and antiepileptic mood stabilizer treatment response in bipolar disorder: what do we know?

Abstract

References